Ramat Gan, Israel, August 17, 2026
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and oncology diseases, announced new preclinical results evaluating Aramchol in combination with enzalutamide (XTANDI®) in prostate cancer models. The company reported that the combination produced a 3- to 4-fold increase in cancer cell death compared with enzalutamide alone in a VCaP prostate cancer cell-line model. The findings represent Galmed’s first reported prostate oncology results involving Aramchol and support the company’s interest in investigating the compound as a potential combination therapy with established prostate cancer treatments. The company emphasized that the results are preclinical and will require further research and clinical validation before any conclusions can be made about potential patient benefit.
Aramchol and Enzalutamide Show Enhanced Cell Killing
The study evaluated the combination of Aramchol, an SCD1 inhibitor, with enzalutamide, an androgen receptor blocker used in prostate cancer treatment. Galmed reported that the combination generated a 3- to 4-fold increase in cell death compared with enzalutamide as a single agent, with the interaction becoming stronger as the treatment duration increased. The research used the VCaP prostate cancer cell line, which features high expression of wild-type androgen receptors, the clinically relevant AR-V7 splice variant, and the TMPRSS2-ERG gene fusion. The cell line was derived from a vertebral metastasis of a patient with metastatic castration-sensitive prostate cancer. These characteristics make the model relevant to the biological mechanisms being investigated, although laboratory findings from a cell-line model do not establish clinical efficacy in patients.
SCD1 Inhibition May Address Drug Resistance
Galmed’s research is based on the role of lipid metabolism in prostate cancer adaptation and treatment resistance. According to the company, recent research indicates that prostate cancer cells can adapt to standard-of-care treatments such as enzalutamide by modifying lipid metabolism. Both enzalutamide-sensitive and resistant cells depend on lipid desaturation pathways, creating a potential opportunity to combine androgen-receptor blockade with SCD1 inhibition. By targeting lipid synthesis and desaturation alongside androgen signaling, the combination may reduce cancer-cell viability and potentially delay the development of resistance. Galmed previously reported that Aramchol demonstrated synergistic activity with docetaxel (Taxotere®), producing greater-than-additive tumor-cell killing across multiple tumor types where docetaxel is approved, including prostate cancer cells. The latest findings provide additional preclinical support for evaluating Aramchol alongside established prostate cancer therapies.
Advertisement
Galmed Plans Further Development of Combination Strategy
The company said the findings support further evaluation of Aramchol in combination with approved prostate cancer therapies, including enzalutamide with or without a GnRH analogue. Galmed also described a potential treatment strategy in which Aramchol could initially be combined with an anti-androgen and later paired with docetaxel as the anti-androgen effect declines. The company said it is planning discussions with potential partners based on a recently submitted patent application covering the combination. While these plans indicate potential future development opportunities, they remain subject to additional preclinical research, clinical trials, regulatory requirements, and successful development. Galmed is developing Aramchol and related candidates across oncology and other disease areas while also advancing medical-device technology through its subsidiary Colospan. For cGxP.wire readers, the announcement is significant because it highlights an emerging combination-therapy approach in prostate oncology, linking metabolic pathway inhibition with established androgen-receptor-targeted treatment. The reported increase in cell death provides an early research signal, but further studies will be needed to determine whether the preclinical findings translate into meaningful therapeutic benefits in humans.
Source: Galmed Pharmaceuticals press relese
